A detailed history of Engineers Gate Manager LP transactions in Karyopharm Therapeutics Inc. stock. As of the latest transaction made, Engineers Gate Manager LP holds 48,133 shares of KPTI stock, worth $30,805. This represents 0.0% of its overall portfolio holdings.

Number of Shares
48,133
Previous 28,700 67.71%
Holding current value
$30,805
Previous $24,000 62.5%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.7 - $1.06 $13,603 - $20,598
19,433 Added 67.71%
48,133 $39,000
Q4 2023

Feb 14, 2024

SELL
$0.68 - $1.31 $6,978 - $13,443
-10,262 Reduced 26.34%
28,700 $24,000
Q3 2023

Nov 14, 2023

BUY
$1.14 - $1.81 $28,542 - $45,316
25,037 Added 179.8%
38,962 $52,000
Q2 2023

Aug 14, 2023

BUY
$1.79 - $4.59 $24,925 - $63,915
13,925 New
13,925 $24,000
Q4 2022

Feb 14, 2023

BUY
$2.48 - $5.93 $46,529 - $111,258
18,762 Added 60.94%
49,552 $168,000
Q3 2022

Nov 14, 2022

SELL
$4.08 - $5.82 $74,003 - $105,563
-18,138 Reduced 37.07%
30,790 $168,000
Q2 2022

Aug 15, 2022

BUY
$4.15 - $8.37 $203,051 - $409,527
48,928 New
48,928 $221,000
Q1 2022

May 16, 2022

SELL
$5.91 - $14.38 $166,662 - $405,516
-28,200 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$5.21 - $8.61 $169,840 - $280,677
-32,599 Reduced 53.62%
28,200 $181,000
Q3 2021

Nov 15, 2021

BUY
$4.45 - $10.63 $203,894 - $487,055
45,819 Added 305.87%
60,799 $354,000
Q2 2021

Aug 16, 2021

SELL
$8.11 - $11.11 $432,522 - $592,518
-53,332 Reduced 78.07%
14,980 $155,000
Q1 2021

May 17, 2021

BUY
$9.85 - $17.69 $450,657 - $809,352
45,752 Added 202.8%
68,312 $719,000
Q4 2020

Feb 16, 2021

SELL
$14.15 - $17.19 $213,834 - $259,775
-15,112 Reduced 40.11%
22,560 $349,000
Q3 2020

Nov 16, 2020

BUY
$14.14 - $19.71 $348,522 - $485,812
24,648 Added 189.25%
37,672 $550,000
Q2 2020

Aug 17, 2020

BUY
$16.6 - $25.25 $216,198 - $328,856
13,024 New
13,024 $247,000

Others Institutions Holding KPTI

About Karyopharm Therapeutics Inc.


  • Ticker KPTI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 79,806,600
  • Market Cap $51.1M
  • Description
  • Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...
More about KPTI
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.